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ABSTRACT
Objective: There have been calls to remove
‘carcinoma’ from terminology for in situ cancers such
as ductal carcinoma in situ (DCIS), to reduce
overdiagnosis and overtreatment. We investigated the
effect of describing DCIS as ‘abnormal cells’ versus
‘pre-invasive breast cancer cells’ on women’s concern
and treatment preferences.
Setting and participants: Community sample of
Australian women (n=269) who spoke English as their
main language at home.
Design: Randomised comparison within a community
survey. Women considered a hypothetical scenario
involving a diagnosis of DCIS described as either
‘abnormal cells’ (arm A) or ‘pre-invasive breast cancer
cells’ (arm B). Within each arm, the initial description
was followed by the alternative term and outcomes
reassessed.
Results: Women in both arms indicated high concern,
but still indicated strong initial preferences for watchful
waiting (64%). There were no differences in initial
concern or preferences by trial arm. However, more
women in arm A (‘abnormal cells’ first term) indicated
they would feel more concerned if given the alternative
term (‘pre-invasive breast cancer cells’) compared to
women in arm B who received the terms in the
opposite order (67% arm A vs 52% arm B would feel
more concerned, p=0.001). More women in arm A also
changed their preference towards treatment when the
terminology was switched from ‘abnormal cells’ to
‘pre-invasive breast cancer cells’ compared to arm B.
In arm A, 18% of women changed their preference to
treatment while only 6% changed to watchful waiting
(p=0.008). In contrast, there were no significant
changes in treatment preference in arm B when the
terminology was switched (9% vs 8% changed their
stated preference).
Conclusions: In a hypothetical scenario, interest in
watchful waiting for DCIS was high, and changing
terminology impacted women’s concern and treatment
preferences. Removal of the cancer term from DCIS
may assist in efforts towards reducing overtreatment.
INTRODUCTION
Ductal carcinoma in situ (DCIS) is a pre-
invasive malignancy of the breast. Since the
onset of organised breast screening, its inci-
dence has rapidly increased, with DCIS
representing approximately 20% of screen-
detected cancers.1 In the USA, approxi-
mately 50 000 women are diagnosed with
DCIS each year2 and in Australia, around
1600 women are diagnosed annually.3
Although DCIS is divided into three grades
with different rates of progression (suggested
estimates range between 14% and 53% and
are uncertain);4 it is almost always treated as
if it were invasive cancer, with most women
receiving either a mastectomy (20 000/year
in the USA)5 6 or a lumpectomy, often com-
bined with radiation therapy. A recent review
by the Independent UK Panel on Breast
Strengths and limitations of this study
▪ This is the first study to assess the effects of
alternative terms for ductal carcinoma in situ
(DCIS) on both psychological outcomes and
treatment preferences.
▪ Participants were a national community sample
including women from a range of demographic
backgrounds.
▪ The experimental design allowed inclusion of
participants who were unbiased by previous
knowledge and information about DCIS.
▪ Limitations of the study include its hypothetical
design, therefore women facing a real diagnosis
of DCIS may respond differently.
▪ Preferences for watchful waiting were predicated
on the statement, ‘if research shows watchful
waiting is a safe and effective option’; the
subject of two current randomised trials of
women with DCIS.
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Cancer Screening7 concluded that there is sizeable over-
diagnosis and overtreatment of screen-detected breast
lesions including DCIS. Although the review did not sep-
arate DCIS and invasive breast cancer in the overdiagno-
sis estimates (19% as a proportion of cancers diagnosed
during the screening period, or 11% of breast cancer
incidence during screening and for the remainder of
the woman’s lifetime), it is widely appreciated that the
proportion of overdiagnosis is likely greater among
DCIS cases. Accordingly, watchful waiting has been pro-
posed as a potentially appropriate alternative treatment
strategy for DCIS.8
It is well recognised that DCIS is challenging to define
and explain, with clinicians and health-care professionals
divided in opinion and practice about how to communi-
cate it to patients.9–11 The common terms used to
describe DCIS include pre-cancer, carcinoma, intraduc-
tal breast cancer, stage 0 cancer and non-invasive cancer;
this terminology has been suggested as a potential driver
of both confusion about the meaning of diagnosis, and
distinction between DCIS and invasive cancer,12 13 and a
desire for more invasive treatments.8 Experts have
recently suggested that the terms cancer or carcinoma
should be removed from the label and instead be
reserved for conditions that are likely to progress if left
untreated.14–16 Alternative terminologies removing the
cancer label have been suggested,8 14 15 and include
ductal intraepithelial neoplasia and indolent lesions of
intraepithelial origin (IDLE).
This study set out to examine whether the use of ter-
minology including the term cancer to describe DCIS,
increased hypothetical concern and treatment prefer-
ences among a community sample of Australian
women.
METHOD
Design
We used a randomised design within a broader community
survey with female participants randomised into one of
two information arms (figure 1). All participants received
information about a hypothetical scenario describing
DCIS without using the term DCIS itself (box 1), and par-
ticipants were asked to imagine the hypothetical diagnosis
were given to them. Arms A and B differed based on the
order of terms used to describe the DCIS condition.
Participants in arm A first received the term ‘abnormal
cells’, while participants in arm B received the term ‘pre-
invasive breast cancer cells’. Measures of concern and
treatment preference for the hypothetical diagnosis were
taken at this time point (time 1). Participants in both arms
were then asked to imagine the same scenario with the
alternative term used to describe DCIS and were again
asked to indicate their level of concern and treatment
preference (time 2). By switching the term within the
arms, we were able to analyse the effect of changing the
terminology both between participants and within
participants.
Setting and participants
Participants were 269 Australian women aged 18 years
and above, who spoke English as their main language at
home.
The initial sample size calculation for the broader
survey was performed with the objective of estimating
proportions with acceptable precision for the entire
sample. The sample of women used in this analysis pro-
vided at least 90% power to detect differences of 20%
between any two proportions compared with a χ2 test
and using a significance level of 0.05.
Figure 1 Study design.
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Procedures
The survey was carried out by the Social Research Centre
(SRC), an independent research agency. A dual frame
random digit dialling sample design was employed with a
50:50 split between landline and mobile samples. On
calling the randomly selected telephone numbers, inter-
viewers requested to speak with the person in the house-
hold aged 18 years or over who had the last birthday
(landlines) or confirmed if the phone answerer was over
18 years of age (mobiles). Once a potential participant
was established, interviewers provided information about
the research purpose and process, and obtained
informed consent. The total survey took approximately
15 min. Analysis of the DCIS scenario was conducted on
female participants (n=269) only.
Measures
Participants were given the scenario as described, and
asked their initial level of concern and their initial treat-
ment preference between treatment (surgery, radiation
or drugs) or watchful waiting. The terminology in each
arm was then alternated and the outcomes (concern and
treatment preferences) were assessed again (figure 1).
Time 1 measures
1. Concern: How concerned would you be about your result?
Five-point Likert scale ranging from extremely concerned to
not concerned at all.
2. Treatment preference: If research shows that watchful
waiting is a safe and effective option, how do you think you
would prefer to manage these abnormal cells/pre-invasive
breast cancer cells?
Five-point response option scale: definitely prefer treat-
ment, probably prefer treatment, prefer to do nothing, prob-
ably prefer watchful waiting (close monitoring by doctors),
definitely prefer watchful waiting.
Time 2 measures
The following statement was read:
Thinking again about the previous scenario, if these abnormal
cells/pre-invasive breast cancer cells were instead called pre-
invasive breast cancer cells/abnormal cells [switched terminology],
1. Change in concern: Would you be more concerned or less
concerned about your screening test result? Three-point
response options: more concerned, no difference, less
concerned.
2. Treatment preference: As above for time 1.
Analysis
Responses for level of concern were combined into
three categories: extremely concerned, moderately
concerned and not concerned/no opinion. Responses
for treatment preferences were combined into two cat-
egories: prefer treatment and prefer watchful waiting.
χ2 Tests were used to compare the level of concern
and treatment preferences between arms based on the
terminology given at each time point in the survey.
The difference within groups regarding treatment
options according to the change of terminology was
tested using MacNemar’s test. There were a limited
number of missing values with a maximum of 8%
missing cases for a variable (see online supplementary
appendix 2). We used a complete case analysis assum-
ing missing completely at random. The significance
level was set at 0.05 and the data were analysed using
SPSS V.22.
RESULTS
A total of 3307 telephone calls were made to recruit 500
survey participants. Of these, 1282 telephone numbers
were eligible, 620 people agreed to participate and 500
participants (both men and women) completed the full
survey with 282 women included in the initial analysis of
the DCIS scenario. Thirteen women reported that they
had had or currently have breast cancer, and were
excluded, leaving a total of 269 women in the analysed
sample (figure 2). The overall adjusted response rate for
the survey was 48%. Participants were from a variety of
demographic backgrounds, and varied in their experi-
ence with cancer screening and diagnosis (table 1), and
included a higher proportion of women around breast
screening and diagnostic age. Although the sample
included a large proportion of women with low levels of
education (48%), overall, the women in our study had
slightly higher levels of education than those of the
general Australian population.
Box 1 Description of ductal carcinoma in situ (DCIS) and
treatment options*
Initial terminology
Breast screening (mammograms) detects changes of cells in the
breast as well as finding breast cancers. In some women these
[abnormal cells/pre-invasive breast cancer cells] can progress to
invasive cancer and in others they do not. It is estimated that, if
left untreated, about one-third may progress to breast cancer over
10 years or more. That means that for about two-thirds of women
these [abnormal cells/pre-invasive breast cancer cells] may not
become cancer.
Imagine you had an abnormal breast screen and follow-up tests
showed that there were [abnormal cells/pre-invasive breast cancer
cells] found in your breast…
Treatment description
[Abnormal breast cells/ pre-invasive breast cancer cells] are
usually treated by surgery, radiation or drugs, as in the case of
breast cancer. Another approach is called watchful waiting, where
doctors closely monitor the [abnormal cells/pre-invasive breast
cancer cells] with regular mammograms and only treat if cells
become more abnormal.
Alternative terminology
Thinking again about the previous scenario, if these [abnormal
cells/pre-invasive breast cancer cells] in your breast were instead
called [pre-invasive breast cancer cells/abnormal cells] (rather
than [abnormal cells/pre-invasive breast cancer cells]).
*See online supplementary appendix 1 for the complete scenario
and measures used.
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Concern about diagnosis
Initial concern (assessed at time 1)
As shown in table 2, initial concern was high in both
arms with 47% of women across arms indicating they
would be ‘extremely concerned’ and 48% ‘moderately
concerned’ following a diagnosis of the condition
described (DCIS). There were no statistically significant
differences between arm A (‘abnormal cells’) and arm B
(‘pre-invasive breast cancer cells’) for women, with 49%
and 44%, respectively, indicating they would be
‘extremely concerned’, p=0.60 (table 2).
Change in concern (assessed at time 2)
When the alternative term was used at time 2, the major-
ity of women across arms stated they would be ‘more
concerned’ (60%). However, women in arm A (initially
given ‘abnormal cells’, then ‘pre-invasive breast cancer
cells’ terminology) were significantly more likely to
report increased concern than women in arm B who
received information in the alternative order (67% vs
52%, p=0.001) (figure 3).
Treatment preferences
Initial treatment preferences (assessed at time 1)
Overall initial treatment preferences for watchful waiting
were high (64%). There were no statistically significant
differences in treatment preferences between arm A
(‘abnormal cells’) and arm B (‘pre-invasive breast
cancer cells’) for women (33% and 41% of women,
respectively, favouring treatment, p=0.23).
Change in treatment preference (assessed at time 2)
There were within-group differences observed in the
change in treatment preferences when terms were
switched. Women in arm A were more likely to prefer
treatment at time 2 when the terminology was switched
from ‘abnormal cells’ to ‘pre-invasive breast cancer
Table 1 Demographic characteristics
Characteristic
Number of survey
respondents, n=269 (%)
Age, years
18–29 36 (13.4)
30–49 78 (29.0)
50–69 109 (40.5)
≥70 46 (11.1)
Education
<High school 44 (17.8) *(26.9)
Completed high school
education only
81 (30.1) *(38.7)
Bachelor degree/advanced
diploma
91 (33.8) *(26.5)
>Bachelor degree 49 (18.2) *(7.7)
Experience with cancer screening
Breast cancer 173 (64.3)
Other forms of cancer 144 (53.5)
*Australian population data from the Australian Bureau of Statistics
2011 Census.
Figure 2 Participant recruitment.
*Out of scope participants
included persons under age
18 years, those whose main
language spoken at home was
not English and those who had a
medical condition rendering them
physically unable to complete the
interview (DCIS, ductal carcinoma
in situ).
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cells’, but there were no differences in arm B. In total,
18% of the women in arm A changed their preference
to treatment when the terminology switched from
‘abnormal cells’ to ‘pre-invasive breast cancer cells’,
while only 6% changed their preference to watchful
waiting (p=0.008) (figure 3 and online supplementary
appendix 3). No significant treatment preference
changes were observed in arm B (9% vs 8%, p>0.99).
DISCUSSION
In a randomised comparison of terms for DCIS among a
national community sample of women, interest in
watchful waiting was high irrespective of the terminology
used. Changes in level of concern and treatment prefer-
ences were observed when terms with and without the
word cancer were alternated. Women who received the
‘abnormal cells’ terminology first reported being signifi-
cantly more concerned when given the alternative ter-
minology (‘pre-invasive breast cancer cells’) at time
2. Women also indicated increased preferences for treat-
ment when terminology was switched from ‘abnormal
cells’ to ‘pre-invasive breast cancer cells’. This pattern
was not observed when women were presented the ter-
minology in the opposite order (cancer term first then
‘abnormal cells’ second). Overall, these findings suggest
Table 2 Women’s level of concern and treatment preferences by terminology (n=269)
Women randomised to
Total (n=269) (%)
Arm A
‘Abnormal cells’
first (n=141) (%)
Arm B
‘Pre-invasive breast cancer
cells’ first (n=128) (%) p value
If presented with the initial terminology you would be
Extremely concerned 47 49 44
Moderately concerned 48 45 51 0.60
Not concerned/No opinion 5 6 5
If presented with the alternative terminology you would be
More concerned 60 67 52
No difference 24 15 35 0.001
Less concerned 16 18 13
If presented with the initial terminology you would
Prefer treatment 36 33 40 0.23
Prefer watchful waiting 64 67 60
If presented with the alternative terminology you would
Prefer treatment 43 45 41 0.51
Prefer watchful waiting 57 55 59 0.008*
>0.99†
*McNemar’s test comparing the change in treatment preferences according to terminology used, for Arm A.
†McNemar’s test comparing the change in treatment preferences according to terminology used, for Arm B.
Figure 3 Change in concern and treatment preference for women (n=269).
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that terminology including the word cancer in a hypo-
thetical scenario can influence level of concern and
treatment preferences.
Although it has recently been stated that removal of
the term cancer may reduce anxiety and desire for more
invasive treatments,15–18 we could find only one research
letter directly addressing this issue.19 That study of 394
women without breast cancer also found that women
were more likely to choose surgery for treatment of
DCIS when a cancer term (non-invasive cancer) was used
compared with non-cancer terms breast lesion or abnormal
cells. Forty-seven per cent of the women opted for
surgery when the cancer term was used compared to
34% and 31% when the terms breast lesion and abnor-
mal cells were used, respectively.19 In contrast to Omer,
we did not find a difference in initial treatment prefer-
ences between the cancer and non-cancer terms;
however, our study has important advantages in that it
assessed the use of alternative terms within the same
individuals and found a significant effect on both a psy-
chological outcome (concern) and treatment prefer-
ences. Our study was conducted among a national
community sample with a high proportion of older
women from lower educational backgrounds. It is
unclear how women in Omer’s study were recruited, the
response rate and whether they were a clinic or conveni-
ence sample. Their sample also included a higher pro-
portion of adults with tertiary education and, indeed,
high numeracy was found to be a predictor of treatment
preferences in the study.
Women in our sample demonstrated higher levels of
interest in watchful waiting. In addition to the demo-
graphic differences already described, this finding may
be explained in part by different treatment options pre-
sented in each study: treatment (including medication)
versus watchful waiting in our study in contrast to
surgery, medication or active surveillance presented by
Omer et al.
The overall level of concern to a hypothetical DCIS
diagnosis was, not surprisingly, high. However, we had
not anticipated the high level of interest in watchful
waiting: 64% (initial treatment preference overall). The
term watchful waiting was used in our questions to parti-
cipants and it was also described as ‘close monitoring by
doctors’. Importantly, the questions were explicitly predi-
cated on the statement, ‘if research showed it to be a
safe and effective option’, as has been shown in treat-
ment for early stage prostate cancer20–22 and is currently
being trialled for DCIS.23 24 In addition, it was clearly
stated that the woman diagnosed could proceed to treat-
ment (surgery, radiotherapy, medical management) in
the future if needed, as would be the case in clinical
practice. This was included following results from
research by Gavaruzzi et al,25 which indicated greater
endorsement for active treatment when watchful waiting
excluded possible treatment in the future.
There were strengths as well as limitations to our
study. First, our sample was a national community
sample of women, which included a comparatively high
proportion of women with lower levels of education
(48%), that is, they either did not complete high school
or had no post-high school qualifications (age 18 years).
Women of all ages were included in the study since it is
possible (although rare) for women outside the screen-
ing age to receive a diagnosis of DCIS. Our sample,
however, did include a higher proportion of older
women of screening age.
The study was limited by its hypothetical design as
women facing a real diagnosis of DCIS may respond dif-
ferently to participants in our survey. However, the
experimental design allowed us to include participants
who were unbiased by previous knowledge and informa-
tion about DCIS, and enabled the use of standardised
scenarios that could be directly compared. It is currently
extremely difficult to test different terminologies among
women diagnosed with DCIS (outside a clinical trial of
watchful waiting for DCIS) since this needs to be a treat-
ment option supported by clinicians. This may not be
the case until rates of progression of DCIS to invasive
cancer and the impact of watchful waiting is better estab-
lished and understood through randomised controlled
trials of this strategy.23 24 Testing women who have
already received a diagnosis would not be meaningful
since responses would be biased by their previous treat-
ment decisions and the previous terminology used by
clinicians. We also note that we gave participants an esti-
mated population average for the risk of progression
from DCIS to invasive cancer to ensure clarity and com-
prehension of the scenario. In practice, risk of progres-
sion is likely to vary according to age, tumour grade and
other factors, and more individually tailored information
would be given to patients. Furthermore, we note that
the significant difference observed in arm A when terms
were switched from non-cancer to cancer is unlikely to
be a result of demand characteristics from the study
design (with women feeling obliged to change their
response). If this were the case, the same pattern would
be expected in both randomised arms, but it was not
observed in arm B. In addition, the changes we observed
in arm A were in the same direction and consistent for
both outcomes; concern and treatment preference.
There is growing concern about the problem of over-
diagnosis and overtreatment of inconsequential disease.
One strategy to mitigate this problem may be to change
the terminology currently used to describe cancer-
related conditions that have low malignant potential,15
such as DCIS. This could potentially encourage clini-
cians and patients to both opt for more conservative
treatment strategies such as watchful waiting, although it
would have to be part of a broader effort to support con-
servative treatment. Our research shows that a national
sample of women demonstrated high levels of interest in
watchful waiting, which has not previously been reported
and supports the need for the two trials currently under-
way on this topic.23 24 Switching terminology from
‘abnormal cells’ to ‘pre-invasive breast cancer’
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influenced women’s concern and treatment preferences
at least in a hypothetical setting. Together, the findings
provide evidence that further investigation of the effects
of changing DCIS terminology is needed in clinical
populations as removing the cancer term may reduce
concern and overtreatment, as proposed by Esserman
et al.15 At minimum it shows that language is a powerful
tool that has the potential to shape both understanding
and actions.
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